FdaApplication
NDA 211675
Identifiers
- fda_app_no: NDA211675
Properties
| Property | Value |
|---|---|
| applicant_name | ABBVIE INC |
| application_type | NDA |
| approval_date | 2019-08-16 |
Revenue by product
RINVOQ
| Period | Revenue |
|---|---|
| Q2 2026 | $2.5B |
| Q1 2026 | $2.1B |
| Q4 2025 | $2.4B |
| Q3 2025 | $2.2B |
| Q2 2025 | $2.0B |
| Q1 2025 | $1.7B |
| Q4 2024 | $1.8B |
| Q3 2024 | $1.6B |
| Q2 2024 | $1.4B |
| Q1 2024 | $1.1B |
| Q4 2023 | $1.3B |
| Q3 2023 | $1.1B |
| Q2 2023 | $918.0M |
| Q1 2023 | $686.0M |
| Q4 2022 | $770.0M |
| Q3 2022 | $695.0M |
| Q2 2022 | $592.0M |
| Q1 2022 | $465.0M |
| Q4 2021 | $517.0M |
| Q3 2021 | $453.0M |
| Q2 2021 | $378.0M |
| Q1 2021 | $303.0M |
| Q4 2020 | $281.0M |
| Q3 2020 | $215.0M |
| Q2 2020 | $149.0M |
| Q1 2020 | $86.0M |
| Q4 2019 | $33.0M |
| Q3 2019 | $14.0M |
| Q2 2019 | $0.0M |
| Q1 2019 | $0.0M |
| Q4 2018 | $0.0M |
| Q3 2018 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (3)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| RINVOQ | UPADACITINIB | 30MG | TABLET, EXTENDED RELEASE;ORAL |
| RINVOQ | UPADACITINIB | 15MG | TABLET, EXTENDED RELEASE;ORAL |
| RINVOQ | UPADACITINIB | 45MG | TABLET, EXTENDED RELEASE;ORAL |
3 products